# A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.

> clinical trial · VERIFIED · 2026-08-03

Status: RECRUITING · Sponsor: Nanjing Bioheng Biotech Co., Ltd. · Condition: SLE

- Company: Nanjing Bioheng Biotech Co., Ltd.
- Sector: biotech
- Primary source: https://clinicaltrials.gov/study/NCT07203404

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.